Trial Profile

A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 29 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TPX-0131 (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms FORGE-1
Sponsors Turning Point Therapeutics

Most Recent Events

24 May 2023 Status changed from active, no longer recruiting to discontinued.
07 Nov 2022 Status changed from recruiting to active, no longer recruiting.
18 Jan 2022 According to a Turning Point Therapeutics media release, the company anticipates providing early interim data from initial patients treated in the dose-finding portion of the FORGE-1 study in the fourth quarter of 2022 or early 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com